Search

Displaying results 1881 - 1890 of 8573 in total
  1. Drug

    Methionine

    go.drugbank.com/drugs/DB00134
    ApprovedInvestigationalNutraceutical

    A sulfur containing essential amino acid that is important in many body functions. It is a chelating agent for heavy metals.

    Mixtures: EAS ORAL 100 TABLET
  2. Drug

    Teclistamab

    go.drugbank.com/drugs/DB16655
    ApprovedInvestigational

    [L43612] Teclistamab was later granted accelerated approval by the FDA on October 25, 2022.[L43617] … [A253587] On August 24, 2022, the European Commission (EC) granted conditional marketing authorization of teclistamab as first-in-class bispecific antibody for the treatment of multiple myeloma, marking

  3. Drug

    Finasteride

    go.drugbank.com/drugs/DB01216
    ApprovedInvestigational

    [L6244,L10565] In 1998, it was approved by the FDA to treat male pattern hair loss. … It works in a similar fashion as [dutasteride], which is another 5-alpha-reductase inhibitor, by exerting antiandrogenic effects.

  4. Drug

    Potassium

    go.drugbank.com/drugs/DB14500
    ApprovedInvestigational

    It was identified as a shortfall nutrient by the 2015-2020 Advisory Committee of Dietary Guidelines for Americans. … Hypokalemia (low potassium) or hyperkalemia (high potassium) may result, manifesting as various signs and symptoms.

  5. Drug

    Metreleptin

    go.drugbank.com/drugs/DB09046
    ApprovedInvestigational

    [L41315] In February 2014, metreleptin was approved by the FDA for the treatment of complications of leptin deficiency, as an adjunct to diet, in patients with congenital generalized or acquired generalized … [A263126] Complications of lipodystrophy include metabolic abnormalities such as hypertriglyceridemia, insulin resistance, diabetes mellitus, and fatty liver disease.

  6. Drug

    Pantoprazole

    go.drugbank.com/drugs/DB00213
    ApprovedInvestigational

    [A177577, A177580] Pantoprazole doses should be slowly lowered, or tapered, before discontinuing as rapid discontinuation of PPIs such as pantoprazole may cause a rebound effect and a short term increase … [FDA Label] Due to their good safety profile and as several PPIs are available over the counter without a prescription, their current use in North America is widespread.

    Products: PANTO-GAS
  7. Drug

    Lisdexamfetamine

    go.drugbank.com/drugs/DB01255
    ApprovedInvestigational

    [A2230] Lisdexamfetamine is the first chemically formulated prodrug stimulant [A40246] and was first approved by the FDA in April 2008.[A2230] It was also approved by Health Canada in February 2009. … Lisdexamfetamine is a prodrug of [dextroamphetamine], a central nervous system stimulant known as d-amphetamine,[A40246] covalently attached to the naturally occurring amino acid L-lysine.

  8. Drug

    Insulin glargine

    go.drugbank.com/drugs/DB00047
    ApprovedInvestigational

    As of 2015, insulin glargine was reformulated by Sanofi as the product Toujeo in an extra-concentrated form containing 300IU/mL (compared to 100IU/mL contained in Lantus). … Insulin glargine is also available as the biosimilar, or "follow-on" product, Basaglar in the US and as Abasaglar in the EU.

  9. Drug

    Proparacaine

    go.drugbank.com/drugs/DB00807
    ApprovedVet approved

    It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.

  10. Drug

    Lutetium Lu-177 vipivotide tetraxetan

    go.drugbank.com/drugs/DB16778
    ApprovedInvestigational

    [L41280] Lutetium Lu-177 vipivotide tetraxetan was first approved by the FDA on March 23, 2022 as a treatment for prostate-specific membrane antigen–positive metastatic castration-resistant prostate … [L43787] In December 2022, lutetium Lu-177 vipivotide tetraxetan was approved by the EMA.[L43787,L45533]